AstraZeneca Meets All Key Goals in Phase III Hypertension Study

Key Takeaways AZN's baxdrostat met all primary and secondary endpoints in a phase III study for uncontrolled hypertension. Both 1 mg and 2 mg doses showed significant SBP reductions and were well-tolerated over 12 weeks. AZN got baxdrostat via CinCor acquisition; late-stage studies for additional indications are also underway.AstraZeneca (AZN) reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patient ...